These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1612904)

  • 1. [Intralesional therapy of melanoma metastases with recombinant interferon-beta].
    Fierlbeck G; d'Hoedt B; Stroebel W; Stutte H; Bogenschütz O; Rassner G
    Hautarzt; 1992 Jan; 43(1):16-21. PubMed ID: 1612904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of locoregional metastases of malignant melanomas with radiotherapy and intralesional beta-interferon injection.
    Paul E; Müller I; Renner H; Bödeker RH; Cochran AJ
    Melanoma Res; 2003 Dec; 13(6):611-7. PubMed ID: 14646625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma.
    Mastrangelo MJ; Maguire HC; Eisenlohr LC; Laughlin CE; Monken CE; McCue PA; Kovatich AJ; Lattime EC
    Cancer Gene Ther; 1999; 6(5):409-22. PubMed ID: 10505851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study.
    Kowalzick L; Rogozinski T; Wimheuer R; Pilz J; Manske U; Scholz A; Fierlbeck G; Mohr P; Ochsendorf F; Wagner G; Gaus W; Brzoska J; Jablonska S
    Eur J Dermatol; 2002; 12(6):558-61. PubMed ID: 12459527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comment on the contribution by G. Fierlbeck, B. d'Hoedt, W. Stroebel, H. Stutte, O. Bogenschütz and G. Rassner. Intralesional therapy of melanoma metastases with recombinant interferon-beta].
    Kölmel KF; Abel U
    Hautarzt; 1993 May; 44(5):329-30. PubMed ID: 8320124
    [No Abstract]   [Full Text] [Related]  

  • 6. [Bowenoid actinic keratosis: therapy with intralesional injection of recombinant beta-interferon].
    Kowalzick L; Mensing H; Weyer U; Kimmig W; Brzoska J
    Hautarzt; 1992 Jun; 43(6):373-5. PubMed ID: 1628972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Significant survival advantage in 96 treated patients in comparison with 288 untreated symptomatic controls].
    Beiteke U; Ruppert P; Garbe C; Oxenfarth R; Kastl I; Türker T; Tronnier H; Frosch PJ
    Hautarzt; 1993 Jun; 44(6):365-71. PubMed ID: 8335459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma.
    Richtig E; Ludwig R; Kerl H; Smolle J
    Br J Dermatol; 2005 Nov; 153(5):925-31. PubMed ID: 16225601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interferon therapy in malignant melanoma].
    Stadler R; Garbe C
    Z Hautkr; 1990 May; 65(5):504-7. PubMed ID: 1696048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic response of interferon-beta in malignant melanoma].
    Ishihara K
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):1010-6. PubMed ID: 2421645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intralesional therapy of metastatic spreading melanoma with beta-interferon.
    Rapprich H; Hagedorn M
    J Dtsch Dermatol Ges; 2006 Sep; 4(9):743-6. PubMed ID: 16928243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic use of alpha interferon in metastasizing malignant melanoma, disseminated Kaposi sarcoma and severe Behçet disease].
    Stadler R; Bratzke B; Orfanos CE
    Hautarzt; 1987 Aug; 38(8):453-60. PubMed ID: 3654216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perilesional treatment of metastatic melanoma with interferon-beta.
    Fujimura T; Okuyama R; Ohtani T; Ito Y; Haga T; Hashimoto A; Aiba S
    Clin Exp Dermatol; 2009 Oct; 34(7):793-9. PubMed ID: 19438554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical effect and histopathologic observation of malignant melanoma by intratumoral administration of HuIFN- beta].
    Ishihara K; Hayasaka K; Yamamoto A
    Gan No Rinsho; 1983 May; 29(6):603-7. PubMed ID: 6876428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
    Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
    Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma.
    Khorana AA; Rosenblatt JD; Sahasrabudhe DM; Evans T; Ladrigan M; Marquis D; Rosell K; Whiteside T; Phillippe S; Acres B; Slos P; Squiban P; Ross M; Kendra K
    Cancer Gene Ther; 2003 Apr; 10(4):251-9. PubMed ID: 12679797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-beta therapy for malignant melanoma: the dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells.
    Kubo H; Ashida A; Matsumoto K; Kageshita T; Yamamoto A; Saida T
    Arch Dermatol Res; 2008 Jul; 300(6):297-301. PubMed ID: 18324409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma.
    Ridolfi L; Ridolfi R
    Hepatogastroenterology; 2002; 49(44):335-9. PubMed ID: 11995445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in immunological parameters after combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-beta (DAV + IFN-beta therapy) into malignant melanoma.
    Umeda T; Aoki K; Yokoyama A; Ohara H; Hayashi O; Tanaka K; Nishioka K
    J Dermatol; 1998 Sep; 25(9):569-72. PubMed ID: 9798342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.